Technical Analysis for CRDF - Cardiff Oncology, Inc.

Grade Last Price % Change Price Change
F 9.72 5.88% 0.54
CRDF closed up 5.88 percent on Friday, March 5, 2021, on 73 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CRDF trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Multiple of Ten Bearish Other 5.88%
Wide Bands Range Expansion 5.88%
Fell Below 200 DMA Bearish -3.86%
Wide Bands Range Expansion -3.86%
Crossed Above 200 DMA Bullish -12.43%
Wide Bands Range Expansion -12.43%
Older End-of-Day Signals for CRDF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 12 hours ago
Down 10% about 13 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Fell Below Lower Bollinger Band about 14 hours ago
Down 5% about 14 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cardiff Oncology, Inc. Description

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Oncology Lymphoma Cancer Treatments Prostate Cancer Phosphate Chemotherapy Acute Myeloid Leukemia Antineoplastic Drugs Leukemia Targeted Therapy Colorectal Cancer Takeda Pharmaceutical Company Advanced Solid Tumors Resistant Prostate Cancer Solid Tumor Cancers Adenosine Leukemias Metastatic Colorectal Cancer Metastatic Castration Resistant Prostate Cancer Chemotherapies Nektar Therapeutics

Is CRDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.5
52 Week Low 0.701
Average Volume 2,074,118
200-Day Moving Average 10.98
50-Day Moving Average 13.73
20-Day Moving Average 11.59
10-Day Moving Average 10.28
Average True Range 1.17
ADX 21.55
+DI 15.28
-DI 38.10
Chandelier Exit (Long, 3 ATRs ) 11.44
Chandelier Exit (Short, 3 ATRs ) 11.76
Upper Bollinger Band 14.54
Lower Bollinger Band 8.65
Percent B (%b) 0.18
BandWidth 50.84
MACD Line -1.10
MACD Signal Line -1.05
MACD Histogram -0.0561
Fundamentals Value
Market Cap 343.36 Million
Num Shares 35.3 Million
EPS -2.73
Price-to-Earnings (P/E) Ratio -3.56
Price-to-Sales 848.95
Price-to-Book 21.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.08
Resistance 3 (R3) 11.84 10.83 11.68
Resistance 2 (R2) 10.83 10.23 10.94 11.55
Resistance 1 (R1) 10.27 9.86 10.55 10.51 11.42
Pivot Point 9.26 9.26 9.40 9.37 9.26
Support 1 (S1) 8.70 8.66 8.98 8.94 8.02
Support 2 (S2) 7.69 8.29 7.80 7.89
Support 3 (S3) 7.13 7.69 7.76
Support 4 (S4) 7.37